AI Article Synopsis
- The development and manufacturing of COVID-19 vaccines occurred at an exceptionally rapid pace due to unprecedented resource allocation, intense collaboration between public and private sectors, and innovative technologies and processes.
- Key factors in this acceleration included new vaccine platforms and streamlined clinical trial procedures, showcasing how effective partnerships can enhance scientific progress.
- The insights from the COVID-19 vaccine experience suggest that similar strategies and investments could be vital for tackling future epidemics and global health issues.
Article Abstract
Coronavirus disease 2019 (COVID-19) vaccine development and manufacturing have proceeded at a historically unprecedented pace. This speed may be accounted for by the unprecedented scale of resources being devoted to addressing COVID-19; an unusual intensity of cooperation, encompassing the public and private sectors and occurring both within and across national borders; and innovation with respect to both technologies (for example, new vaccine platforms) and processes (for example, vaccine clinical trials). In this article we describe and analyze how resources, cooperation, and innovation have contributed to the accelerated development of COVID-19 vaccines. Similar levels and types of public investment, models of cooperation, and harnessing of innovative processes and technologies could be applied to future epidemics and other global health challenges.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1377/hlthaff.2020.02012 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!